arrow
S

Samer Al Hadidi

Simmons Comprehensive Cancer Center
H指数:20
被引数:1,662

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Prognostic impact of lymphocyte kinetics and immune composition during bispecific antibody therapy in relapsed/refractory multiple myeloma

在复发/难治性多发性骨髓瘤的双特异性抗体治疗期间,淋巴细胞动力学和免疫组成的预后影响

2026-08-220
OAAI
Correction: Clinical outcomes and risk factors of cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients

更正:接受teclistamab治疗的多发性骨髓瘤患者中巨细胞病毒再激活的临床结局和危险因素

2026-08-070
OAAI
Impact of extramedullary plasmacytoma on outcomes in patients with relapsed refractory multiple myeloma treated with talquetamab: U.S. Myeloma Immunotherapy Consortium
2026-07-270
OA
Clinical outcomes and risk factors of cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients

细胞巨病毒再激活的临床结局和危险因素:在teclistamab治疗的复发性/难治性多发性骨髓瘤患者中

2026-03-310
OAAI
Peripheral blood immune cell profiling and response to BCMA CAR-T cell therapy in relapsed refractory multiple myeloma

外周血免疫细胞特征分析及对BCMA CAR-T细胞治疗的反应,在复发难治性多发性骨髓瘤中的应用

2026-01-060
OAAI
Optimizing oncology drug development: systematic review of 22 years of myeloma randomized controlled trials

优化肿瘤药物开发:22年多发性骨髓瘤随机对照试验的系统综述

2025-11-090
OAAI
Talquetamab in relapsed refractory multiple myeloma: multi-institutional real-world study

Talquetamab在复发难治性多发性骨髓瘤中的应用:多中心真实世界研究

2025-11-070
OAAI
Equal survival for Black Americans with multiple myeloma when appropriately matched to White Americans

黑人美国人和白人美国人在多发性骨髓瘤患者适当匹配时的生存率相同

2025-10-160
OA